Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan;38(1):145-56.
doi: 10.1007/s10545-014-9749-9. Epub 2014 Aug 5.

Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency

Maria Andrea Desbats  1 , Giada Lunardi, Mara Doimo, Eva Trevisson, Leonardo Salviati
Affiliations
Review

Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency

Maria Andrea Desbats et al. J Inherit Metab Dis. 2015 Jan.

Abstract

Coenzyme Q(10) is a remarkable lipid involved in many cellular processes such as energy production through the mitochondrial respiratory chain (RC), beta-oxidation of fatty acids, and pyrimidine biosynthesis, but it is also one of the main cellular antioxidants. Its biosynthesis is still incompletely characterized and requires at least 15 genes. Mutations in eight of them (PDSS1, PDSS2, COQ2, COQ4, COQ6, ADCK3, ADCK4, and COQ9) cause primary CoQ(10) deficiency, a heterogeneous group of disorders with variable age of onset (from birth to the seventh decade) and associated clinical phenotypes, ranging from a fatal multisystem disease to isolated steroid resistant nephrotic syndrome (SRNS) or isolated central nervous system disease. The pathogenesis is complex and related to the different functions of CoQ(10). It involves defective ATP production and oxidative stress, but also an impairment of pyrimidine biosynthesis and increased apoptosis. CoQ(10) deficiency can also be observed in patients with defects unrelated to CoQ(10) biosynthesis, such as RC defects, multiple acyl-CoA dehydrogenase deficiency, and ataxia and oculomotor apraxia.Patients with both primary and secondary deficiencies benefit from high-dose oral supplementation with CoQ(10). In primary forms treatment can stop the progression of both SRNS and encephalopathy, hence the critical importance of a prompt diagnosis. Treatment may be beneficial also for secondary forms, although with less striking results.In this review we will focus on CoQ(10) biosynthesis in humans, on the genetic defects and the specific clinical phenotypes associated with CoQ(10) deficiency, and on the diagnostic strategies for these conditions.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. N Engl J Med. 2014 Jul 3;371(1):80-1 - PubMed
    1. Ochsner J. 2010 Spring;10(1):16-21 - PubMed
    1. J Med Genet. 2012 Mar;49(3):187-91 - PubMed
    1. Lancet. 2000 Jul 29;356(9227):391-5 - PubMed
    1. J Biol Chem. 2010 Sep 3;285(36):27827-38 - PubMed

Publication types

MeSH terms

Supplementary concepts